https://www.selleckchem.com/products/peg400.html
3% and 10.5% in ETV group (OR 16.4, 95% CI 6.6-40.0, P.001) respectively. Subgroup analysis showed that switching to TAF achieved favours CVR regardless of the status of ****, age, CHB family history, HBV DNA, HBeAg and cirrhosis, whereas alcohol consumption and diabetes mellitus might compromise the CVR of switching to TAF. Both therapies were well tolerated and had satisfying renal safety. For ETV-treated patients with LLV, switching to TAF is safe enough and superior compared with continuing ETV monotherapy regarding both virologic
Me gusta
Comentario
Compartir
